Search results for "Aggregation"

showing 10 items of 566 documents

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Blood rheology effect of submaximal exercise on young subjects

2013

Nowadays cardiac and metabolic diseases are a matter of concern. Exercise is a valid treatment and method of prevention for not only adults, but also young subjects. Physical activity causes transient blood rheology impairment in adults. However little is known about the effects of exercise on blood flow characteristics in young subjects. The aim of the study was to assess the effects of a light aerobic exercise session on blood rheology in young subjects. Ten young subjects (aged 12-16 years) performed 1 hour of submaximal aerobic exercise (70% HRmax). Blood samples were drawn just before and after exercise. We determined blood and plasma viscosity, fibrinogen, erythrocyte deformability an…

Malemedicine.medical_specialtyAdolescentPhysiologyBlood viscosityHematocritFibrinogenErythrocyte aggregationPhysiology (medical)Internal medicinemedicineHumansAerobic exerciseErythrocyte deformabilityPlasma VolumeChildExercisemedicine.diagnostic_testbusiness.industryFibrinogenHematologyBlood flowHematocritHemorheologyCardiologyPhysical therapyFemaleHemorheologyCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Percutaneous closure of left atrial appendage to prevent embolic events in high-risk patients with chronic atrial fibrillation

2009

Background: Percutaneous closure of the left atrial appendage (LAA) is a novel alternative for the treatment of patients with atrial fibrillation (AF) and with a high risk of stroke who are not eligible for long-term anticoagulation therapy. The aim of this study was to asses the safety, feasibility, and long-term efficacy of this procedure. Methods: From July 2004 to June 2007, 20 patients (13 male, mean age 69 ± 8 years) with non–valvular AF (NV-AF) underwent LAA percutaneous closure using the PLAATO™ system, implanted through a transeptal access. All patients had contraindications to anticoagulant therapy and were at high risk for cardioembolic stroke (mean CHADS2 score 3 ± 1.2). A trans…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsThromboembolism.left atrial appendage occlusionmedicine.medical_treatmentEmbolismSettore MED/11 - Malattie dell'Apparato CardiovascolareTransesophagealLeft atrial appendage occlusionPericardial effusionRisk AssessmentLeft atrialInternal medicineAtrial FibrillationmedicineHumansRadiology Nuclear Medicine and imagingAtrial Appendageatrial fibrillation; left atrial appendage occlusion; thromboembolism; Aged; Atrial Fibrillation; Contraindications; Echocardiography Transesophageal; Embolism; Equipment Design; Feasibility Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Stroke; Time Factors; Treatment Outcome; Anticoagulants; Atrial Appendage; Cardiac Catheterization; Chronic DiseaseStrokeAgedbusiness.industryContraindicationsAnticoagulantsAtrial fibrillationGeneral MedicineEquipment DesignthromboembolismMiddle Agedmedicine.diseaseSurgeryStrokeTreatment OutcomePericardiocentesisEchocardiographyChronic DiseaseCardiologyPatent foramen ovaleFeasibility StudiesFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealPlatelet Aggregation Inhibitors
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

The relationship between the rheological behavior of RBCs and angiogenesis in the morbidly obese

2018

OBJECTIVE The aim of this study was to investigate the relationship between red blood cell (RBC) aggregation and deformability and angiogenesis parameters in obese patients. METHODS We studied 35 obese subjects and 20 non-obese people as a control group. Angiogenesis was detected using Bio-Plex Pro Human Angiogenesis Multiplex Assays. The RBC aggregation and deformability of the red blood cell aggregation were performed by the Laser-assisted Optical Rotational Cell Analyser - LORCA. RESULTS The aggregation index and the syllectogram's amplitude were significantly higher in the obese patients, whereas the aggregation half-time (t1/2) was lower compared with the control group. The deformabili…

Malemedicine.medical_specialtyErythrocytesPhysiologyAngiogenesisVEGF receptors030204 cardiovascular system & hematologyMorbidly obeseIndependent predictor030218 nuclear medicine & medical imagingCardiovascular Physiological Phenomena03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineObese groupHumansMedicinebiologybusiness.industryAngiopoietin 2HematologyObesity MorbidRed blood cell aggregationRed blood cellmedicine.anatomical_structureEndocrinologybiology.proteinFemaleRheologyCardiology and Cardiovascular MedicinebusinessClinical Hemorheology and Microcirculation
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle.

1997

We investigated the effects of isoliquiritigenin and YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole) on tension in endothelial-free rat aortic rings precontracted with phenylephrine (3 microM). Both compounds induced a concentration-dependent relaxation (EC50 of YC-1 1.9 microM and of isoliquiritigenin 9.4 microM). The effects developed faster with YC-1 than with isoliquiritigenin, and the effects of YC-1 were potentiated by isoliquiritigenin (10 microM). 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (30 microM) inhibited the effect of YC-1, but not of isoliquiritigenin. These results suggest that the effects of YC-1 are due to stimulation of soluble guanylyl cyclase activity, whereas …

Malemedicine.medical_specialtyIndazolesPhosphodiesterase InhibitorsMuscle RelaxationStimulationMuscle Smooth VascularRats Sprague-Dawleychemistry.chemical_compoundChalconeChalconesAldehyde ReductaseInternal medicinemedicineAnimalsEnzyme InhibitorsPhenylephrinePharmacologybiologyDose-Response Relationship DrugChemistryBiological activityRatsDose–response relationshipEndocrinologyCarotid ArteriesMechanism of actionEnzyme inhibitorGuanylate Cyclasebiology.proteinFemalemedicine.symptomSoluble guanylyl cyclaseIsoliquiritigeninPlatelet Aggregation Inhibitorsmedicine.drugMuscle ContractionEuropean journal of pharmacology
researchProduct

Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.

2010

408 Positional cerebral ischemia (PCI) is an extremely rare condition in which dramatic central nervous system deficits are triggered by standing in patients with severe stenosis or occlusion of the major brain-supplying blood vessels [1] . Because PCI is generally associated with orthostatic hypotension [2, 3] , a hemodynamic mechanism has been proposed [4] . However, PCI has been reported even in patients without orthostatic hypotension [1] . The treatment is medical, but surgery can be considered in refractory cases (endarterectomy for carotid artery stenosis or either highor low-flow extra-intracranial bypass – for carotid occlusion) [3] . We report a case of PCI associated with middle …

Malemedicine.medical_specialtyMiddle Cerebral ArterySettore MED/09 - Medicina InternaTiclopidinePostureIschemiaHemodynamicsOrthostatic vital signsmedicine.arteryInternal medicineParietal LobeOcclusionmedicineHumansThrombophiliacardiovascular diseasesCerebral perfusion pressureTomography Emission-Computed Single-Photonpositional ischemia Extracranial by-passAspirinCerebral Revascularizationbusiness.industryInfarction Middle Cerebral ArteryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingClopidogrelTemporal ArteriesParesisHemiparesisBlood pressureNeurologyIschemic Attack TransientAnesthesiaMiddle cerebral arteryCardiologyNeurology (clinical)medicine.symptomCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsCerebrovascular diseases (Basel, Switzerland)
researchProduct

Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo

1993

The aim of our study was to evaluate the platelet antiaggregatory and hemodynamic effects of the stable prostacyclin analog iloprost and the NO-donor SIN-1, an active metabolite of molsidomine. The number of circulating platelets was determined in anesthetized male Wistar rats as a measure of in vivo platelet aggregation. Platelet count decreased from 648 +/- 25 to 476 +/- 15 x 10(3) platelets/microliter and from 578 +/- 36 to 411 +/- 40 (mean +/- SEM) in response to two repetitive injections of collagen (70 micrograms/kg body weight). Treatment with SIN-1 bolus injections (0.3 or 1 mg/kg bw) and/or continuous i.v. infusion of iloprost (0.2 or 0.4 micrograms/kg bw/min) was initiated 15 min …

Malemedicine.medical_specialtyMolsidominePlatelet AggregationPlatelet aggregationBlood PressureProstacyclinNitric Oxidechemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsPlateletIloprostRats WistarAntihypertensive AgentsActive metaboliteChemistryDrug SynergismHematologyRatsEnzyme ActivationEndocrinologyGuanylate CyclaseMolsidomineAdenylyl Cyclase InhibitorsPlatelet Aggregation InhibitorsSignal TransductionIloprostmedicine.drugGuanylate cyclaseThrombosis Research
researchProduct